Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL6 (Roche): FCR with or without mitoxantrone in previously untreated chronic lymphocytic leukaemia
ISRCTN42165735Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of fludarabine, cyclophosphamide, rituximab and mitoxantrone in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Complete response rate. Started Jun 2009; status: completed.
02
Drugs
fludarabinecyclophosphamiderituximabmitoxantrone
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN42165735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42165735.